NEW YORK, Dec. 01, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely
On Thursday, shares in Bedford, Ohio headquartered ViewRay Inc. recorded a trading volume of 1.32 million shares, which was above their three months average volume of 719.37 thousand shares. The stock ended the session 4.22% higher at $9.63. The Company's shares have gained 39.77% in the last month, 83.08% over the previous three months, 192.71% in the past twelve months, and 207.67% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 34.35% and 49.08%, respectively. Moreover, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have a Relative Strength Index (RSI) of 68.01. Get started with a complimentary subscription and access to the free report on VRAY at: www.wallstequities.com/registration/?symbol=VRAY
Sunnyvale, California headquartered Accuray Inc.'s stock closed the day 0.96% lower at $5.15 with a total trading volume of 1.18 million shares, which was above their three months average volume of 732.20 thousand shares. The Company's shares have advanced 24.10% in the previous three months and 11.96% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.51% and 14.08%, respectively. Additionally, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 62.46.
On November 30th, 2017, research firm Lake Street initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. Free research on ARAY can be accessed at: www.wallstequities.com/registration/?symbol=ARAY
Shares in Marietta, Georgia headquartered MiMedx Group Inc. recorded a trading volume of 2.40 million shares. The stock ended yesterday's trading session 3.58% higher at $11.57. The Company's shares have advanced 22.05% in the past twelve months and 30.59% on an YTD basis. The stock is trading below its 50-day moving average by 5.21%. Furthermore, shares of MiMedx, which develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare, have an RSI of 49.41. Sign up today for the free research report on MDXG at: www.wallstequities.com/registration/?symbol=MDXG
Marlborough, Massachusetts headquartered Boston Scientific Corp.'s stock finished Thursday's session 1.27% higher at $26.28 with a total trading volume of 18.57 million shares, which was above their three months average volume of 6.09 million shares. The Company's shares have advanced 28.45% in the past twelve months and 21.50% since the start of this year. The stock is trading below its 50-day moving average by 8.40%. Additionally, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 31.10.
On November 30th, 2017, research firm BTIG Research upgraded the Company's stock rating from 'Neutral' to 'Buy'. Wall St. Equities' research coverage also includes the downloadable free report on BSX at: www.wallstequities.com/registration/?symbol=BSX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-medical-equipment-equities----viewray-accuray-mimedx-and-boston-scientific-300565017.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All